284 related articles for article (PubMed ID: 33856094)
1. Salvage Treatment Using Anti-PD-1/CTLA-4 Immunotherapy After Failure of Neoadjuvant Chemotherapy in Microsatellite Instable Gastroesophageal Carcinoma.
Klein O; Brown WA; Saxon S; Haydon A
Oncologist; 2021 Jun; 26(6):461-464. PubMed ID: 33856094
[TBL] [Abstract][Full Text] [Related]
2. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
André T; Tougeron D; Piessen G; de la Fouchardière C; Louvet C; Adenis A; Jary M; Tournigand C; Aparicio T; Desrame J; Lièvre A; Garcia-Larnicol ML; Pudlarz T; Cohen R; Memmi S; Vernerey D; Henriques J; Lefevre JH; Svrcek M
J Clin Oncol; 2023 Jan; 41(2):255-265. PubMed ID: 35969830
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
Front Immunol; 2022; 13():795972. PubMed ID: 35371084
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
Haag GM; Czink E; Ahadova A; Schmidt T; Sisic L; Blank S; Heger U; Apostolidis L; Berger AK; Springfeld C; Lasitschka F; Jäger D; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2019 Apr; 144(7):1697-1703. PubMed ID: 30499151
[TBL] [Abstract][Full Text] [Related]
6. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171
[No Abstract] [Full Text] [Related]
7. Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538.
Klein O; Senko C; Carlino MS; Markman B; Jackett L; Gao B; Lum C; Kee D; Behren A; Palmer J; Cebon J
Oncoimmunology; 2021 Apr; 10(1):1908771. PubMed ID: 33889439
[No Abstract] [Full Text] [Related]
8. Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resistance to Pembrolizumab: A Case Report and Literature Review.
Gim G; Kim Y; Park Y; Kim MJ; Nam M; Yang W; Duarte SE; Jung CM; Vagia E; Viveiros P; Chae YK
Oncologist; 2022 Jul; 27(7):525-531. PubMed ID: 35640145
[TBL] [Abstract][Full Text] [Related]
9. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in synchronous MSI-H rectal adenocarcinoma and upper tract urothelial carcinoma: a case report.
Hsieh-Wong J; Liu J; Huynh J; Parikh M; Kim E; Gong J; Halabi W; Siricilla M; Mitra A; Toomey K; Cho M
J Gastrointest Oncol; 2022 Jun; 13(3):1473-1480. PubMed ID: 35837187
[TBL] [Abstract][Full Text] [Related]
11. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series.
Pan T; Yang H; Wang WY; Rui YY; Deng ZJ; Chen YC; Liu C; Hu H
Clin Colorectal Cancer; 2024 Mar; 23(1):104-110. PubMed ID: 38336555
[TBL] [Abstract][Full Text] [Related]
13. Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?
Sabanathan D; Park JJ; Marquez M; Francisco L; Byrne N; Gurney H
Oncologist; 2017 Dec; 22(12):1470-1477. PubMed ID: 29146617
[TBL] [Abstract][Full Text] [Related]
14. A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma.
Pothuri V; Herndon J; Ballentine SJ; Lim KH; Fields RC
Oncologist; 2021 Sep; 26(9):722-726. PubMed ID: 33982365
[TBL] [Abstract][Full Text] [Related]
15. Combination of CTLA-4 and PD-1 blockers for treatment of cancer.
Rotte A
J Exp Clin Cancer Res; 2019 Jun; 38(1):255. PubMed ID: 31196207
[TBL] [Abstract][Full Text] [Related]
16. Management of Microsatellite Instability High (MSI-H) Gastroesophageal Adenocarcinoma.
Zhou KI; Hanks BA; Strickler JH
J Gastrointest Cancer; 2023 Dec; ():. PubMed ID: 38133871
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer.
Kanani A; Veen T; Søreide K
Br J Surg; 2021 Dec; 108(12):1417-1425. PubMed ID: 34694371
[TBL] [Abstract][Full Text] [Related]
18. Pathological complete response after neoadjuvant immunotherapy combined with chemotherapy in pediatric rectal carcinoma: A case report.
Cao X; Luo J; Zhao B; Fu H; Kang W
Front Immunol; 2022; 13():1036181. PubMed ID: 36544760
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability.
Kohlruss M; Grosser B; Krenauer M; Slotta-Huspenina J; Jesinghaus M; Blank S; Novotny A; Reiche M; Schmidt T; Ismani L; Hapfelmeier A; Mathias D; Meyer P; Gaida MM; Bauer L; Ott K; Weichert W; Keller G
J Pathol Clin Res; 2019 Oct; 5(4):227-239. PubMed ID: 31206244
[TBL] [Abstract][Full Text] [Related]
20. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]